May 1, 2019 - Denosumab appears to be effective in reducing the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Treatment with denosumab does not increase the risk of cancer or death but might increase the risk of infection. However, more studies are required.
American Family Physician : Medicine by the Numbers
Aug 15, 2003 - ...head-to-head comparisons of medical and nonmedical interventions would improve our current approach to osteoporosis prevention. A limited number of studies of nonmedical interventions, such as exercise, adequate intake of calcium and vitamin D,11 and the use of hip protectors in...
American Family Physician : Editorials
Sep 15, 1999 - Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are...
American Family Physician : Article
Feb 15, 2016 - You do not have to treat a low vitamin D level if your patient is a typical community-dwelling postmenopausal woman younger than 75 years. The usual dosage of vitamin D, 800 IU (20 mcg) daily, will not increase levels even after a year of therapy and has little effect on calcium ...
American Family Physician : POEMs
navigate_before 1 navigate_next